Target- |
MechanismCell replacements |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.US |
First Approval Date20 Nov 2024 |
/ Active, not recruitingPhase 2 A Randomized Controlled Phase IIa, Two-arm Study to Assess the Safety and Efficacy of Human Umbilical Cord Blood (RegeneCyte) Infusion in Patients with Post-COVID Syndrome
RegeneCyte (HPC, Cord Blood, hUCB) for treatment in patients with post-COVID.
A Randomized Controlled Phase II, Two-Arm Study of Umbilical Cord Blood Cell Transplant (MC001) Into Injured Spinal Cord Followed by the Locomotor Training for Patients with Chronic Complete Spinal Cord Injuries (SCI).
Umbilical cord blood mononuclear stem cells (UCBMSCs) transplant followed by the intensive locomotor training for up to 5±1 hours a day, 5±1 days a week, and for 3-6 months for treatment in patients with chronic, stable and complete spinal cord injury.
100 Clinical Results associated with Stemcyte International Ltd.
0 Patents (Medical) associated with Stemcyte International Ltd.
100 Deals associated with Stemcyte International Ltd.
100 Translational Medicine associated with Stemcyte International Ltd.